Methotrexate and the Risk of Lung Disease Save
Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.
Clinical criteria for the diagnosis of MTX pneumonitis (acute, reversible) and RA-ILD (chronic, progressive) are quite different and are reviewed in this article.
Despite the large numbers of clinical trials that include MTX, very few of these are suitable for use to analyse the risk of MTX pneumonitis.
Continue Reading
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject
The author has an ownership interest in this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.